A veterinary vaccine using RNA technology and originally developed by Merck & Co has received a positive opinion from the European Medicines Agency on the basis of multiple, positive studies in cats. The vaccine, Nobivac NXT HCPChFeLV, contains live attenuated strains of five feline viruses, one of which is a strain of the feline leukaemia virus. This virus strain suppresses the immune system and is a common cause of cancer in cats. It is species specific and does not affect humans.
